By: Dr. Lori Thompson, task force chair
The AVMA’s Task Force on Veterinary Compounding Legislation held its second in-person meeting in Washington, D.C., Dec. 8-9, where they continued discussions on how compounding is used in the veterinary profession.
The group is tasked with developing a legislative proposal pursuant to the AVMA policies on compounding in veterinary medicine. As part of this process, they are meeting with stakeholders to better understand compounding for veterinary medicine.
At their December meeting, they delved into topics of importance to the profession: maintaining office stock, compounding from bulk ingredients, adverse event reporting, and quality assurance. They also considered the role that drug shortages and the preservation of the Food and Drug Administration’s approval process play in the access to compounded preparations. Discussions were also held with representatives from the Accreditation Commission for Health Care (ACHC), of which the Pharmacy Compounding Accreditation Board’s accreditation for non-sterile and sterile pharmacy compounding is a service, and Wildlife Pharmaceuticals, Inc., a company that provides pharmaceuticals for the care of non-domestic and exotic wildlife species.
In the near future, the task force hopes to meet with a representative from the U.S. Pharmacopeial Convention (USP), which is a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines manufactured, distributed and consumed worldwide. They also plan to review a revised version of the Compliance Policy Guide Sec. 608.400 Compounding of Drugs for Use in Animals, which the FDA is expected to release in the new year.
For more information on background on the task force’s charge, visit AVMA’s Web page.